Effect of time on human muscle outcomes during simulated microgravity exposure without countermeasures – systematic review.

Winnard, A.*¹, Scott J², Waters, N.¹, Vance, M.¹, & Caplan, N.¹

¹Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom
²Space Medicine Office, European Astronaut Centre, Cologne, Germany

Corresponding author:
Dr Andrew Winnard
Faculty of Health and Life Sciences
Northumbria University
Northumberland Building
Newcastle upon Tyne
NE1 8ST
Tel: +44 (0)191 243 3217
Email: A.Winnard@northumbria.ac.uk

Keywords:
Muscle
Microgravity
Spaceflight
Deconditioning
Astronaut

Words:
Abstract: 360
Main text: 8063
Figures: 13
Tables: 2
Abstract

Background
Space Agencies are planning human missions beyond Low Earth Orbit. Consideration of how physiological system adaptation with microgravity (µG) will be managed during these mission scenarios is required. Exercise countermeasures (CM) could be used more sparingly to decrease limited resource costs, including periods of no exercise. This study provides a complete overview of the current evidence, making recommendations on the length of time humans exposed to simulated µG might safely perform no exercise considering muscles only.

Methods
Electronic databases were searched for astronaut or space simulation bed rest studies, as the most valid terrestrial simulation, from start of records to July 2017. Studies were assessed with the Quality in Prognostic Studies and bed rest analogue studies assessed for transferability to astronauts using the Aerospace Medicine Systematic Review Group Tool for Assessing Bed Rest Methods. Effect sizes, based on no CM groups, were used to assess muscle outcomes over time. Outcomes included were contractile work capacity, muscle cross sectional area, muscle activity, muscle thickness, muscle volume, maximal voluntary contraction force during one repetition maximum, peak power, performance based outcomes, power and torque/strength.

Results
75 bed rest µG simulation studies were included, many with high risk of confounding factors and participation bias. Most muscle outcomes deteriorated over time with no countermeasures. Moderate effects were apparent by 7-15 days and large by 28-56 days. Moderate effects (>0.6) became apparent in the following order, power and MVC during one repetition maximum (7 days), followed by volume, cross sectional area, torques and strengths, contractile work capacity, thickness and endurance (14 days), then muscle activity (15 days). Large effects (>1.2) became apparent in the following order, volume, cross sectional area (28 days) torques and strengths, thickness (35 days) and peak power (56 days).

Conclusions
Moderate effects on a range of muscle parameters may occur within 7-14 days of unloading, with large effects within 35 days. Combined with muscle performance requirements for mission tasks, these data, may support the design of CM programmes to maximise efficiency without compromising crew safety and mission success when incorporated with data from additional physiological systems that also need consideration.
1. Introduction

1.1. Rationale

Space Agencies are planning to transition from International Space Station (ISS) missions to Lunar missions including a crewed base from which to test and develop hardware and procedures required for the longer term goal of human Mars missions (Foing 2016). It is well documented that exposure to microgravity (µG) during spaceflight causes adaptation in response to gravitational unloading, especially in the musculoskeletal, cardiovascular and neuro-vestibular systems (Buckey 2006, Baker 2008). The risks to mission success due to potential injury or reduced function due to periods of unmanaged adaptation before arriving at a remote location such as Moon or Mars, where medical teams may not be present on landing, need to be addressed (Gernand 2004). Bed rest is often used as a controlled Earth-based environment for simulating the effects of spaceflight on humans to enable more cost-effective, higher quality and safer research into effects and medical management of adaptation (Pavy-Le Traon, Heer et al. 2007). While bed rest fails to remove a Gx (chest-to-back) loading vector, such studies are considered the most valid simulation method for many physiological systems (Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007), except for weight bearing, tissue fluid redistributions and skin surface areas of compression (Hargens and Vico 2016), and when conducted rigorously are likely to generate results transferable to astronauts (Higgins and Green 2011, Winnard and Nasser 2017).

Based on bed rest research and previous spaceflight experience, the ISS provides astronauts with 2.5 hours per day for exercise (including setup, stowage and hygiene) using a treadmill, cycle ergometer and resistance exercise device designed and adapted for µG (Trappe, Costill et al. 2009, Loehr, Lee et al. 2011). Several years of refining ISS exercise countermeasures (CM) has led to astronauts completing 6-month missions with, on average, little to no change in bone mass or cardiovascular capacity, although the efficacy seems to vary widely between individuals (Moore., Downs et al. 2014, English, Lee et al. 2015, Sibonga, Spector et al. 2015), while muscle adaptation appears to have become progressively smaller as exercise devices and prescriptions have improved (Smith, Heer et al. 2012, Moore., Downs et al. 2014, Ploutz-Snyder, Ryder et al. 2015). However, the exercise devices currently aboard ISS will almost certainly be too large and too numerous for, and the exercise prescriptions place too great a demand on the consumables and environmental management systems available on, the vehicles and habitats currently planned for future exploration missions. For this reason, space agencies have started designing smaller, low energy and low vibration exercise devices (Brusco 2016). However, decisions will need to be made regarding choice and/or development of an effective exercise CM programme to manage physiological adaptation that will occur during exploration missions. Considerations may include reducing the frequency of exercise as currently performed on ISS and potentially having longer periods of not performing any exercise. The duration of any such no exercise periods needs to be evidence based to balance any increase physiological risks to crew against gains in spacecraft and consumables impact.

1.2. Objectives
The objectives of this review were to provide a complete summary of and synthesise the current space-related physiological evidence base and to inform decision making processes around muscle performance requirements, regarding operational CM, for exploration human space missions. Where data is lacking for any outcomes this will be highlighted as a gap or limited area of the current evidence base and used to provide a gap analysis commentary useful for future research priority setting. The aim is to aid space agencies in designing CM programmes, provide a complete summary of what muscle groups and outcomes have been assessed in the current evidence and highlight areas of minimal data or research gaps to guide future relevant research in this area. The NASA Risk Table for the Human Research Project highlights potential risks relating to spaceflight and shows the large scope of potential physiological systems that require reviewing to cover all elements of crew health and performance (NASA 2019). As the scope is too large for a single review, it is suggested that the various systems be reviewed individually. Once a series of reviews has been complete a position statement summarising across each system can provide a holistic overview.

Therefore, this specific review investigated the rate at which muscle parameters change during simulated µG exposure, when no countermeasures are taken, to inform operational decisions regarding the possibility of using exercise CM programmes more sparingly for exploration missions, including the implementation of exercise ‘holidays; (i.e. a period of time within the mission when no exercise CM are employed). Conclusions of this review alone must be treated in a muscle context and need considering alongside other relevant health and performance components.

1.3. Research question

At what time point do people exposed to simulated µG while not performing CM reach a moderate or large effect on muscle health outcomes?

2. Methods

2.1. Study design

The Cochrane Collaboration Guidebook (Higgins and Green 2011) and preferred reporting items for systematic reviews and meta-analyses (PRISMA) were adhered to (Moher, Liberati et al. 2009). No external funding or research grants were received for this work.

2.1.1. Participants

The following inclusion criteria were employed. The target population was astronauts, however, as astronauts have taken part in space agency recommended exercise programmes to date, there was no inactive data available from this population. Therefore, healthy terrestrial adults, with no gender restrictions, taking part in µG analogue bed rest studies, were included. Bed rest studies were the only terrestrial model included as they are considered the most valid ground based model for simulating human spaceflight for periods beyond a few minutes (Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007). Therefore to maintain the greatest level of transferability to astronauts and in keeping with our other systematic reviews only bed rest studies that stated they were simulating human spaceflight were considered. No clinical bed rest situations such as critical care were...
included as they would likely have confounding co-morbidities and not transfer well to astronauts. All participants in the included bed rest studies were healthy at baseline, however, no exclusion was made relating to baseline level of physical condition beyond being healthy. Only control group data were relevant, therefore no inclusion criteria were based on interventions. Control groups had to be inactive and not undergo any type of intervention. Included studies had to report outcomes relating to muscles. For completeness of reporting the current state of the evidence base and avoid introducing selection bias, no exclusion was made based on type of outcome or amount of data. The evidence based led outcomes were determined from pre-scoping and the main review searches and were grouped for analysis as cross-sectional area, volume, shape, size, activity, power, performance and joint torque and forces at either a regional or global level. Included studies had to be randomised controlled trials (RCT), controlled clinical trials (CT), longitudinal, interrupted time series or before and after studies.

2.2. Systematic review protocol
2.2.1. Search strategy, data sources, studies sections and data extraction
A range of relevant terms grouped by main search terms were constructed using Boolean logic (astronaut*, spaceflight, space flight, space*, weightless*, microgravity, micro gravity, bed-rest, bedrest, bed rest, dry immersion, muscle*, strength*) to search the following databases up to July 2017: Pubmed, CINAHL, Web of Science, NASA Technical Reports Server and The Cochrane Collaboration Library. No restrictions on type of bed rest or publication dates were applied, and due to the inability to use ‘Boolean logic’ on the NASA Technical Reports Server, the strategy was adapted to keyword searches. The full search strategy is available in Table 1.

*** insert table 1 here ***

Initial screening was performed using abstracts and titles by two authors (MV and AW), blinded to each other’s decisions, using Rayyan (https://rayyan.qcri.org/) (Ouzzani, Hammady et al. 2016). Rayyan also automatically detects duplicate studies and data and all flagged potential duplication was assessed by agreement of three blinded authors. Where there was any disagreement whether the study met the inclusion criteria from initial screening the full text was obtained. A third author (NC) was used to resolve disagreements of included/excluded studies. An adapted version of the Aerospace Medicine Systematic Review Group (AMSRG) ‘Data extraction form’, version 2, July 2017, (AMSRG 2018) was used by two authors (MV and NW) to extract data from each paper, and disagreements were discussed by three authors (AW, NW and MV) to reach consensus.

2.3. Data analysis
2.3.1. Quality assessment
The Quality in Prognostic Studies (QUIPS) tool was used to assess risk of bias of all the included studies, with ‘H’, ‘M’ and ‘L’ showing high, moderate and low risk respectively, using pre-defined published definitions for each level (Hayden, van der Windt et al. 2013). Risk of bias results were used to comment on the current quality and completeness of the
evidence base and do not change how studies were treated during analysis. As per published
recommendations, only studies that were rated low risk of bias in all QUIPS domains were
deed as low risk overall (Hayden, van der Windt et al. 2013). The AMSRG ‘Tool for
Assessing Bed Rest Methods’ (Winnard and Nasser 2017a, Winnard and Nasser 2017) was
used to assess the bed rest methodological quality, and transferability to astronaut
populations, of all included studies, with ‘y’ indicating the point was met, ‘n’ not met and ‘?’
unclear. This is a relatively new tool, yet to be validated, that has been used in several other
reviews (Richter, Braustein et al. 2017, Winnard, Nasser et al. 2017) and the development of
the tool is explained in Winnard et al (2017).

2.3.2. Main analysis

Effect sizes (Hedges’ g) were calculated between pre and post bed rest values for each
outcome individually without an overall pooled effect. Hedges’ g was used to bias correct for
the typically small sample sizes, as only control group data from µG simulation studies were
eventually included. The reported data set that was as close to immediate pre and the end of
bed rest was used for the analysis. No exclusion or analysis variation was made based on the
individual study analysis methods. The pooled standard deviation for Hedges’ g was
calculated using the root mean square of the pre and post group standard deviations. This
version does not specifically include the sample size (n), preventing any complications that
could arise from inflating n when both group means are from the same sample. Results were
first sub-grouped by outcome measure type and then by muscle group before being listed in
order of ascending days spent in simulated µG. Individual effects sizes were calculated and
plotted in figures for each outcome at every time point where data were available. To enable
a brief overview of the large data set to also be provided, an unweighted mean effect at each
common time point within each muscle group was used to provide a summary result. This
was only done when more than one study assessed the same outcome at the same time point.
These statistics were chosen due to data being from the same sample rather than a separate
intervention and control group, thus making a traditional weighted effects meta-analysis
pooling inappropriate. Traditional meta-analysis assumes two different sets of individuals in
each group (Higgins and Green 2011) meaning a violation of underlying assumptions would
have occurred if applied to this review. The summary unweighted mean, while being a less
robust statistic, enabled an overarching overview to be reported in addition to each individual
effect size, and overlaid on the figures, without violating statistical assumptions. 95%
confidence intervals were calculated for individual and unweighted group means. Readers
should note that due to varying effect sizes across the various muscles and groupings, the
effect size axis scale varies accordingly throughout the figures.

The point at which effects consistently reached a magnitude of 0.6 (moderate) or 1.2 (large)
was highlighted as a time point when a worthwhile mechanistic change had occurred
(Hopkins, Marshall et al. 2009). Plots of all individual effects and 95% confidence interval
tails, in order of ascending days in simulated µG, were overlaid with the mean effect and
polynomial trend line of the mean effects. A polynomial trend allowed for the trend line to
curve in case of progressively worsening, or plateauing patterns. In cases where data were
lacking and varied (spanning more than one effect size cut off between data points), the trend
line was highlighted as likely unreliable in the results section, meaning more data should be
collected before a reliable trend can be established. The limited data sets are however still
included for completeness of reporting the current state of the evidence base and highlight
both minimal data areas and research gaps. The mean effect summary and trend line were
only used to visually highlight the time point at which the mean effects passed the 0.6 and 1.2
magnitude point. A funnel plot of all the mean effects plotted against study size was used to
show potential publication bias.

2.3.3. Sub group analysis

Ten sub groups were created based on the measurement methods units used for each for
analysis as follows (with original units measured in): (1) contractile work capacity (J), (2)
cross sectional area (mm², cm²), (3) muscle activity (µV, mV, normalised), (4) muscle
thickness (mm, cm), (5) muscle volume (cm³), (6) maximal voluntary contraction force
during one repetition maximum (kg, N, Nm) (7), peak power (W), (8) performance based
outcomes (including endurance time, jump power, force, velocity height and acceleration, sit
to stand time, centre of mass variation and sprint time)(s, mm, cm, m, W/kg), (9) power
(rad·s⁻¹, m·s⁻¹) and (10) torques and strength (Nm, ft·lb). Within each subgroup data were
further sub-grouped for analysis by major muscle groups. For completeness of reporting, any
measures that did not fit within major muscle groupings were grouped for analysis and
reported as either “other lower limb”, “other trunk” or “other upper limb” outcomes, to
enable every outcome measure extracted from included studies to be reported in the results.
The outcomes included in the “other” groupings are listed in the text.

3. Results

3.1. Study selection, characteristics and risk of bias

In total, 112 studies were included after duplicates removed, all of which were screened for
inclusion into the analysis. There were 37 not included in the analysis due the reasons
provided in the PRISMA flow diagram (Figure 1). Therefore, 75 studies (Table 2) were
included, producing 922 individual effect sizes across all sub groups and outcomes. All
studies were bed rest µG simulations as no astronaut studies to date included an inactive
control group exposed to µG due to space agency recommended exercise programmes. There
is no comparison descriptor column in table 2 as we only considered control groups who had
no intervention, treated as before and after simulated µG exposure comparisons. The most
common bed rest duration was 60 days, with shortest and longest durations being seven and
120 days, respectively. The most common study design was RCT. Most of the studies
scored four on the bed rest quality score, with the highest score being six, and the lowest
score was two. Only three studies were assessed to have a low risk of bias. As only
intervention studies’ control group data were included and no actual prognostic studies were
found and included, question three on the QUIPS about prognostic factors was rated as n/a
for all the included studies. A rating for question 3 would have been provided had any actual
prognostic studies been found and included. However, for this review, time in µG can be
considered the prognostic factor and the quality of the µG simulation was critiqued in detail
within the bedrest quality scores. There is some asymmetry in the funnel plot in Figure 2,
suggesting potential publication bias toward studies reporting decreases in muscles, however there are studies, including smaller ones, that do report an increase. Forty five studies specified a time period ahead of the bed rest period in which baseline measures were recorded ranging from 1-21 days. Of these, 11 (Greenleaf, Van Beaumont et al. 1983, Dudley, Duvoisin et al. 1989, Greenleaf, Bernauer et al. 1989, Ellis, Kirby et al. 1993, Greenleaf, Lee et al. 1994, Ferrando, Stuart et al. 1995, Portero, Vanhoutte et al. 1996, Muir, Judex et al. 2011, Lee, Schneider et al. 2014, English, Mettler et al. 2016, Schneider, Lee et al. 2016) stated utilising a pre-bed rest ambulatory control period in their methods section. However it was not clear in any of the studies what the control period involved or if there was any pre-bed rest deconditioning that was measured or adjusted for. One study, (Mulder, Gerrits et al. 2008) measured baseline outcomes on day 4 of bed rest and acknowledges this could have led to underestimating the effect of bed rest, especially for time sensitive outcomes such as those associated with muscle. Full data tables for results per muscle are available in supplementary data tables as indicated in each results sub-section. The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any interested parties.

3.2. Synthesised findings

3.2.1. Muscle volume

All muscle volumes decreased over time. Moderate effects were becoming apparent by 14 days and large by 28 days. Very little data were available for Hip Flexor, Gluteal, Multifidus and Erector Spinae muscles, where a moderate or greater effect was never reached for Hip Flexors and Erector Spinae muscles and only a moderate effect was apparent by 27 and 90 days for Gluteal and Multifidus muscles, respectively. Other lower limb muscles that included Gracilis, Sartorius, Piriformis, Obturators and Pectineus muscles, reached a moderate effect by 14 days. Other trunk muscles that included Levator Scapulae, Longus Colli, Sternocleidomastoid and Scalene muscles never reached a moderate effect. The breakdown of individual volume effects per muscle is available in supplementary data Table 3 and associated summary plots in Figure 3.

3.2.2. Muscle cross sectional area

All muscle cross sectional areas decreased over time. Moderate effects were apparent by 14 days and large by 28 days. The same effect time points were found for other lower limb muscles that included Gracilis and Sartorius muscles and total thigh and calf cross sectional area. Very little data were available for Hip Flexor, Gluteal, Hamstring and Hip Adductor muscles where a moderate or greater effect was never reached. Multifidus and other trunk muscles, including Quadratus Lumborum and combined Multifidus and Erector Spinae cross...
314 sectional area, only reached a large effect by 60 days. Upper limb muscle outcomes
315 consisted of forearm muscle cross sectional area which only reached a large effect after 89
316 days. The breakdown of individual cross sectional area effects per muscle are available in
317 supplementary Table 4 and associated summary plots in Figure 4. The polynomial trend for
318 Dorsi Flexor muscles appeared to be unreliable.
319 ***insert Figure 4 here***

320 3.2.3. Torques and strength
321 Torques and strengths decreased over time. Moderate effects became apparent by 14 days for
322 Quadriceps muscles only. Additional moderate effects became apparently by 30 days and
323 large effects by 35 days. Dorsi Flexor, Hamstring, Hip Extensor, Hip Flexor, other trunk and
324 other upper limb muscles never reached a large effect. Other trunk muscles included trunk
325 flexors and extensors tested in combination within functional movements. Upper limb
326 muscles included elbow flexor and extensor muscles and shoulder abductor and adductor
327 muscles. The breakdown of individual torques and strength effects per muscle is available in
328 supplementary Table 5 and associated summary plots in Figure 5. The polynomial trend for
329 Dorsi Flexor muscles appeared to be unreliable after 60 days.
330 ***insert Figure 5 here***

331 3.2.4. Contractile work capacity
332 Although there are very little available data for contractile work capacity it appears to
decrease over time. Moderate effects became apparent by 14 days in Plantar Flexor and
333 Quadriceps muscles. However, this is based on only one study for each muscle at 14 days.
The breakdown of individual contractile work capacity effects per muscle is available in
336 supplementary Table 6 and associated summary plots in Figure 6. Data were limited for all
337 muscles.
338 ***insert Figure 6 here***

339 3.2.5. Muscle thickness
340 Muscle thickness decreased over time. Moderate and large effects became apparent by 14
341 days. There were very little data for Plantar Flexor, Dorsi Flexor and Quadriceps muscles,
342 showing Dorsi Flexor muscles reached a moderate effect by 35 days and only Plantar Flexor
343 and Quadriceps muscles reached a large effect by 35 days. Internal Oblique muscle reached a
344 moderate effect at 14 days. Erector Spinae muscle was similar to Internal Oblique muscle,
345 but only reached a borderline moderate effect within the available data. Upper limb muscles
346 data only included Biceps Brachii muscle thickness, reaching a moderate effect by 35 days.
The breakdown of individual muscle thickness effects per muscle is available in
348 supplementary Table 7 and associated summary plots in Figure 7.
349 ***insert Figure 7 here***

350 3.2.6. Peak power
Peak power decreased over time. Large effects became apparent by 56 days for jump power and 62 days for Plantar Flexor and Quadriceps muscles. There was insufficient data to determine a time point for when any moderate effects were reached. The breakdown of individual peak power effects per outcome is available in supplementary Table 8 and associated summary plots in Figure 8.

***insert Figure 8 here***

3.2.7. Muscle activity

Muscle activity (via electromyography) generally decreased over time, however a transient increase was seen in Plantar Flexor, Dorsi Flexor and Quadriceps muscles and only at 20 days. In Plantar Flexor and Quadriceps muscles, muscle activity decreased again after 20 days, there were no data for Dorsi Flexor muscles beyond 20 days to establish a post 20 day trend. Moderate effects were apparent in upper limb muscle groups by 15 days but not until 90 days for Dorsi and Plantar Flexor muscles which were the only muscles with data at the 90 day point. The breakdown of individual activity effects per muscle is available in supplementary Table 9 and associated summary plots in Figure 9.

***insert Figure 9 here***

3.2.8. Maximal voluntary contraction during one repetition maximum

Maximal voluntary contraction during one repetition maximum decreased over time except for other upper limb outcomes that remained mostly unchanged as far as data were available up to 45 days. Moderate effects became apparent by seven days and large effects by 35 days. Other lower limb outcomes that included maximal isometric force during supine squat, hip extensor force and legs total work never reached a large effect, but had no data available beyond 35 days. The breakdown of individual MVC during one repetition maximum effects per muscle is available in supplementary Table 10 and associated summary plots in Figure 10. The polynomial trend for Hamstring muscles appeared to be unsafe after 20 days.

***insert Figure 10 here***

3.2.9. Power

Power decreased over time. Moderate effects became apparent by 7 days and large effects by 20 days, although these were only seen in the Quadriceps muscle data. Hamstring, Hip Flexor and upper limb muscles that included elbow flexors and extensors reached moderate effects by 20 days. Plantar Flexors never reached a moderate effect but data were only available at 14 days. Other trunk muscles included trunk flexors and extensors tested in combination within functional movements. The breakdown of individual power effects per muscle is available in supplementary Table 11 and associated summary plots in Figure 11.

***insert Figure 11 here***

3.2.10. Performance based
Performance based outcomes all worsened over time, as although sit to stand, balance and sprint time outcomes all had positive effects, this was considered a worsening effect within these measures. Endurance reached a large effect by 14 days, jumping a moderate effect at 42 days and large by 44 days, sit to stand and balance reached large effects by 60 days and sprint time by 62 days. Data for most outcomes were only available for one time point and so trends over time for individual outcomes are not able to be determined. The breakdown of individual performance based effects per outcome is available in supplementary Table 12 and associated summary plots in Figure 12. It should be noted that while these outcomes are grouped as being performance based for this review, they may differ and each individual measure should be considered on its own merit.

4. Discussion

4.1. Summary of main findings

The main finding of the review was that muscle cross-sectional area, volume, shape, size, activity, power, performance, torque and force-based outcomes, at either regional or global level, all decline over time, based on the current evidence base. Moderate effects became apparent in the following order: power and MVC during one repetition maximum (7 days), followed by volume, cross sectional area, torques and strengths, contractile work capacity, thickness and endurance (14 days), then muscle activity (15 days). Large effects became apparent in the following order: volume, cross sectional area (28 days) torques and strengths, thickness (35 days) and peak power (56 days). No large effects were found for muscle activity. There were limited data for contractile work capacity and no large effects were apparent. In general, lower limb and trunk muscles appeared to decline more rapidly than upper limb muscles. Locomotion muscles such as Plantar Flexor and Quadriceps muscles also generally appeared to decline more rapidly than other muscles groups and with larger effect sizes.

4.2. Findings within context of Human space mission profiles

Human spaceflight missions differ in duration, so results have to be placed into the context of mission profiles and operationally important considerations. Operationally, performance-related measures such as power, MVC, torques and strengths are considered most critical. In terms of mission profiles, typical ISS missions involve approximately 180 days in \( \mu G \) (Bryant, Meza et al. 2017). The provision of time for exercise CM is mandated for these missions and developments have led to improved efficacy over the lifetime of ISS (Trappe, Costill et al. 2009, Ploutz-Snyder 2013, Hackney, Scott et al. 2015). Assuming that the rate of change during bed rest is reasonably transferable to that experienced in \( \mu G \), the results of this systematic review suggest that large effects would be apparent within a 180 day ISS mission if no exercise CM were employed. That ISS astronauts are able to complete missions without problems from muscle deterioration and successfully return to Earth may provide some level of evidence with which to judge current countermeasures as effective. However,
The focus of this review is exploration beyond Low Earth Orbit. Lunar and Martian (exploration) mission profiles were defined in the HUMEX study (Horneck, Facius et al. 2006) that modelled exploration mission durations including transit times in µG and planetary stay times in low (<1G) gravity (Figure. 13). HUMEX defined three scenarios, including a Lunar mission with a 180 day surface stay (Horneck, Facius et al. 2003) and two Mars missions with either a 30 or 400 day surface stay (Horneck, Facius et al. 2006). In HUMEX, inter planetary transit time in µG was five days for Lunar missions and 203-213 days for Mars.

***insert Figure 13 here***

4.2.1.1. Mars

It is clear from the findings of this review that changes in muscle outcomes, including performance related measures, with large effects would be observed if no CM were performed during a 200+ day transit to Mars. A risk assessment (Gernand 2004) has highlighted that decreased muscle mass, strength and endurance is likely to lead to inability to complete mission critical tasks such as exiting a spacecraft on landing, performing strenuous extra vehicular activity and being functional during increased G_z loading on non-Earth planetary surfaces where a landing support and rehabilitation team may not be available. Therefore, effective CM to prevent muscle deterioration are likely going to be required for Mars missions unless absolute strength mission requirements can be reduced or eliminated, to mitigate risks of crews being unable to perform mission critical tasks and continue to function safely on arrival at Mars. However, based on the occurrence of large effect sizes in the present results only after 28-35 days, exercise CM ‘holidays’ might be considered during Mars transits/orbits to save resources if agencies were confident that moderate changes in muscle performance could be reversed using in-flight exercise equipment and prescriptions.

4.2.1.2. Moon

The results of this review suggest that exercise CM might not be required during a five day Lunar transit period, as moderate effects on muscle are not likely to be apparent until 7 days. The initial changes in power and MVC might not be functionally limiting enough to risk mission success, compared to muscle size, strength and endurance effects that do not reach a moderate size until 14 days. Therefore, further investigation of any effects within the expected Earth-Lunar transit period, considered against minimal clinically worthwhile and mission critical magnitude changes, may be useful to confirm this finding. As a Lunar landing may occur at 8 days in the HUMEX models, the pre-flight strength of crew and the absolute strength and functional requirements of Lunar landing activities would need to be considered when deciding whether or not employ exercise CM prior to attempting a landing. While not employing exercise CM might be considered for the Earth-Lunar transit period, a recent systematic review of biomechanical responses to reduced gravity (Richter, Braustein et al. 2017) showed that exercise CM would likely be needed during stays on the planetary surfaces of both Moon (0.16g) and Mars (0.38g). As time in both µG and low gravity
accumulates over the entire mission duration (196-d in total for the HUMEX model), exercise CM are also likely to be needed during the return to Earth transit. However, not using exercise CM on the return transit might be considered if key muscle outcomes could be maintained at, or restored to, pre-mission levels by the end of a Lunar surface stay. Based on the occurrence of large effect sizes in the present results, in an off-nominal situation, such as an emergency, a longer period, possibly up to around 30 days, without exercise CM might be considered if the risks of moderate-large effects can be managed in some other way, for example, knowing support and a full rehabilitation programme are available at the destination arrival site. As with Mars missions, for long Lunar orbital missions with extended periods in µG, an exercise CM ‘holiday’ of the same duration might be considered if agencies were confident that moderate changes in muscle performance could be reversed in-flight.

4.2.2. Individuals more susceptible to µG induced muscle changes

An individual with a relatively lower muscle outcome measure may be more susceptible to experiencing a negative functional impact of negative changes in these outcomes compared to someone with greater initial measures. It is expected that most missions will require an absolute (minimal) level of strength to achieve mission critical tasks such as donning/doffing and standing up/moving whilst wearing a space suit in low gravity, hatch opening, and pulling/dragging a fellow crew member wearing a space suit during an emergency. The absolute level is defined as the precise required strength outcome in raw units to achieve a task, as opposed to considering relative changes with effect size or percentage changes. A relative (%) reduction in strength will make all tasks with an absolute strength requirement more challenging for all individuals, but the biggest impact will be felt by those who have a lower initial level of absolute strength. For example, a strong individual might be able to lose 30% of their pre-flight strength and still comfortably achieve a mission critical task (and also still be stronger than a weaker individual was prior to flight), whereas a weaker individual might already be close to their physical limit during this task without any deconditioning. Operationally, having an estimate of the most rapid possible rate of change in muscle outcomes may be useful in the case of a crew member with low pre-flight absolute strength, or an individual highly susceptible to µG adaptation. In the present study, the most extreme negative value within the confidence interval for each outcome provides an estimate of the most extreme worst likely true value that might be encountered with exposure to µG. Based on this estimation, the results of this analysis suggest that the change experienced by an individual astronaut might reach a large effect size in some muscles within a seven day lunar transit period for volume, cross sectional area, contractive work capacity, thickness, power and MVC. However, the confidence intervals are wide due to the small sample sizes across the current evidence base, so this estimate should be treated with caution as it may be exaggerated. Individual effects are difficult to determine in a transferable way to the true population from the data currently available or from individual case studies. Ideally, a population selected for their increased susceptible to unloading/µG-induced muscular adaptation should be studied in a long-duration µG analogue to produce a representable average effect that could be transferred to the true population with more reasonable confidence. Until such data are available, estimating the maximum rate of decline in an
individual in response to \( \mu G \) exposure of such a duration will remain difficult. In addition, consideration would also be needed should an individual be selected to perform some tasks in a mission that are not considered mission critical, but are essential to other mission goals. It may be that checking for susceptibility to outcomes that are linked more strongly to mission success is checked and made part of astronaut eligibility screening, it could also be any more susceptible mission critical individuals undergo more rigorous preflight and inflight training protocols or consider use of other more removed countermeasures beyond the scope of this review.

Exercise countermeasure development may want to consider focussing on those which might best address the more susceptible outcome changes in this review, volume, cross sectional area, contractive work capacity, thickness, power and MVC while also ensuring any proposed exercises are tailored to tasks considered critical, such as donning/doffing and standing up/moving whilst wearing a space suit in low gravity, hatch opening, and pulling/dragging a fellow crew member wearing a space suit. The impact of any chosen exercise types on future spacecraft exercise hardware would also need further consideration. Future research should consider identifying exercise countermeasures that would best address the more susceptible outcomes and be feasible with any technical constraints of new space vehicles planned for use within Moon and Mars missions.

4.2.3. Countermeasure requirement

As CM are likely to be needed on the return trip from both Moon and on the journeys to and from Mars, such CM will need developing. Countermeasure devices should support lower limb and trunk muscle exercise as these decline earlier than other body regions and are essential for locomotion and for spinal function on return to G loading (Bamman 1996, Pavy-Le Traon, Heer et al. 2007, Evetts, Caplan et al. 2014, Stokes, Evetts et al. 2016, Winnard, Nasser et al. 2017a). Based on the results of the present study, if exercise CM are used during very short missions/transits (e.g. up to seven days), devices should support exercise that maintains power and maximal force production, as moderate effects appeared early in these performance outcomes. Up to around 15 days, exercise CM might need only to prevent moderate size effects in muscle. Consideration could be made around if lower intensity exercise, or potentially a break in countermeasures would be safe. However, once \( \mu G \) exposure duration reaches around 30 days and above, large effects in muscle will likely need to be managed and this would likely require devices/prescriptions optimised within the constraints of the vehicle/habitat.

This pattern fits current European Space Agency (ESA) ISS Long Duration Mission (LDM) exercise prescriptions (Petersen, Jaekel et al. 2016) that include an initial 20-day familiarisation phase to allow crew to adjust to exercise in \( \mu G \) and minimise injury risk, in which exercise intensity is moderate compared to pre-flight maximum capacity. However, as there is currently no systematic measurement of muscle performance in-flight, the impact of this period of lower intensity exercise on overall changes in muscle during an LDM is unknown. It is also unclear if crew members may have had better results at the end of a mission had they begun exercising more intensely earlier in the mission. Following the 20-
day familiarisation period, exercise prescriptions are increased in intensity to 80 %+ maximal
capacity. In the final 15-30 days of a long duration mission (greater than 49 days) intensity is
kept high, but focus on resistance and running exercises. In flight resistance exercise
prescriptions for European astronauts also focus on lower limb muscles (squats, heel raises,
deaddlifts) ESA has found are most susceptible to μG induced changes from (non systematic)
measures that have been taken (Petersen, Jaekel et al. 2016). Similar exercise prescriptions,
foocussing on lower limb muscles and maintaining outcomes already highlighted in this
review, might form a good basis for initial planning for any exercises required for Lunar and
Mars missions. Additionally, research on preventing deconditioning of older adults might
also be useful as preventing loss of power in functional lower limb muscles is important in
this population and simple loading exercises have shown helpful in this context (Byrne,
Faure et al. 2016). It should also be noted, however, that a systematic review of in-flight CM
for maintaining spinal health in μG found that, while resistance based exercises helped
prevent muscle changes, they did not help with non-muscle outcomes such as spinal
morphology (Winnard, Nasser et al. 2017a). Moreover, a number of other physiological
systems/organs also adapt to μG, including bone and aerobic capacity, but the efficacy of
resistance exercise during gravitational unloading on them is unknown as systematic reviews
similar to the present study have yet to be performed. Therefore, while the recommendations
of this review are expected to help plan CM for muscle changes, additional holistic
consideration of other physiological systems will likely be required. Finally, any CM
development for exploration missions will also have to consider constraints of space vehicles
that will be used, such as available physical space, limited number of devices that can be
included in the space craft, consumables, generation of heat, carbon dioxide and vibration,
which are likely to be more restricted than the ISS (Hackney, Scott et al. 2015). Before any
pause in exercise countermeasures could be taken, the results of this review would need to be
validated in microgravity and ideally actual astronauts through experimental studies. No
such published studies of astronauts not performing exercise to document muscle changes
over the time frames considered in this review was found. Space agencies and researchers
would also need to consider the ethical implications and acceptability of any such study.

4.3. Completeness and quality of current evidence

There were missing and limited data across all the outcome measure subgroups, and gaps in
the evidence base were clearly shown in the results tables. There was a lack of standardised
time points at which measures were recorded, even across studies reporting the same outcome
measures. Limited data were found repeatedly for Gluteal and Hip Flexor muscles across
several outcome measure subgroups. Data were lacking for contractile work capacity, muscle
thickness and peak power outcome measures where further research is recommended to
validate the trends seen over time in the current evidence base. No patient reported outcome
measures have been reported across the bed rest studies, meaning it is unclear how relevant
the measures are to patients (in this case astronauts) (Dawson, Doll et al. 2010, Nelson,
Eftimovska et al. 2015). In addition, only seven out of the 75 analysed studies considered
functional performance based outcomes that are more likely to be directly relevant to
astronauts. While strong efforts on behalf of space agencies to standardise bed rest studies
has occurred including listing required surrogate measures (Sunblad, Orlov et al. 2014), patient reported outcomes such as their ability to perform a task felt of value to them, remain missing on the whole. It is recommended that the scientific and space medical operations communities agree on set times points at which outcome measures should be tested to enable easier comparisons across studies and for overall trends to be more easily identifiable. While ESA requires agency bed rest studies to be performed to set standards, it might be beneficial to consider running a specific initiative in the wider Aerospace Medicine field to establish core outcome sets relevant to space medicine operations that should then be used in all associated research. This could be based on recommending use of standard space agency developed tests such as functional and Field Test parameters developed by NASA and Russia. The Core Outcome Measures in Effectiveness Trials (COMET) is an example initiative that facilitates development and application of core outcome sets and research has been published on how to reach consensus using such an approach (Prinsen, Vohra et al. 2014). It is also recommended that patient reported outcome measures, and increased reporting of functional performance based outcome measures, be included in both future research and space medical operations to ensure that outcome measures are assessing phenomena that are relevant to astronauts. This recommendation echoes a recent European Space Agency topical team report that also found patient reported outcome measures not being used in space medicine research and operations (Stokes, Evetts et al. 2016). The report recommended the use of such outcomes and suggested potential for development of new such outcome measures specifically for space medicine with operational space medicine input to ensure relevance across research and clinical settings. It would be of further benefit if clinically worthwhile, or concerning, changes were defined for key outcome measures, so that results can be placed into a clinically meaningful context. Reporting results based on clinically meaningful raw changes would likely be more informative to operational decisions compared to the more mechanistic null hypothesis tests, effect size or percentage change measures currently used. The high risk of bias and lack of core outcome measure sets means that the conclusions reached by this review should be treated with some caution. A bed rest study could be performed to confirm the findings of this review. If performed, the study would ideally be a randomised controlled trial comparing inactive bedrest with controls not performing bedrest but controlled for all potential confounding factors. For example, exercise and any other types of muscle interventions would need to be strictly controlled for the period of the study. The bed rest element would ideally comply with all aspects of the AMSRG bed rest quality tool to improve transferability of results to astronauts (Winnard and Nasser 2017). Finally, all modifiable risk of bias elements would need controlling and a risk of bias tool for randomised controlled trials, such as provided by Cochrane (Higgins, Altman et al. 2011), could be used as a guide to check what elements need to be controlled to minimise bias risks. Most of the studies scored four on the bed rest tool, with no studies scoring a full seven points, although thirteen studies scored six. The reasons for marking studies down was mostly due it being unclear if criteria had been met rather than clearly failing a point. The most common unclear criteria was related to restricted sunlight exposure followed by ensuring a fixed daily routine. The high risk of bias results were most commonly caused by not clearly showing how confounding factors were managed and providing adequate
description of participation. The participation domain considers participant eligibility criteria, source of participants, baseline descriptions, description of sampling frame and recruitment, description of period and place of recruitment and inclusion/exclusion criteria (Hayden, van der Windt et al. 2013). The sunlight exposure criteria has more impact on bone outcomes (Holick 2004) due to its role in vitamin D levels within human bone homeostasis (Tarver 2013) so might not be a large concern for the muscle outcomes presented in this review. However, it is recommended that future bed rest protocol information be clear on all the criteria assessed on the bed rest quality tool and especially on the fixed daily routine and restricted sunlight points, while also ensuring that information is provided about control of confounding factors to help reduce risk of bias and participation considerations. In addition, studies that assess time sensitive outcomes, such as muscle (in which the results of this review show effects of deconditioning can occur by 7 days), should report any potential for pre-bedrest deconditioning during familiarisation and baseline measure periods and any attempts to control for this. There is potential that participants who are admitted to bed rest facilities several days in advance for control measures could decondition within this period. Some studies state including an ambulatory control period, but none report details of what this involved or if there was potential for pre-bed rest deconditioning to influence results. There was some asymmetry in the funnel plot showing potential publication bias towards studies reporting a decrease in muscle outcomes. However, there were studies present on the increasing side of the plot, so the risk is not likely to be high. In addition, it is expected that many of the muscle outcomes would decrease during a period of inactivity such as bed rest, therefore, it not surprising most studies reported decreases. Therefore, while it appears a risk of reporting bias may exist, the presence of some studies reporting increases and the expected pattern of more decreases being reporting suggest this finding should be treated with caution and the potential risk is likely to be low.

4.4. Limitations

This review only considered muscle outcomes. Spaceflight is known to affect many more human physiological systems including bone, cardiovascular and vestibular (Pavy-Le Traon, Heer et al. 2007). These results alone, therefore, only provide a muscle based perspective. As typical meta-analysis statistics assume two independent groups (Higgins and Green 2011), a more basic effect size analysis without these assumptions had to be used due to only considering changes over time in the control group of each study. Therefore, some caution should be taken as the mean effect sizes are not weighted and heterogeneity scores are not available. However, as most studies had small sample sizes, a weighted result is not expected to produce largely different results. Additionally, the findings of this review appear to match actual spaceflight findings and patterns, such as the European Space Agency exercise prescription for long duration missions that performs lower intensity exercises for the first 20 days. While actual measures are not taken during flight, the 20 days has so far not resulted in any mission critical functional decline (Petersen, Jaekel et al. 2016). The 20 day period would fit with the findings of this review that only moderate effects would be expected before 28 days and gives some partial validation, from actual astronaut data, to the findings of this review. The review is also broad and, in places, the variation around the outcomes
appears large suggesting heterogeneity of data may be high, although the large intervals could also be due to the small sample sizes that were a common feature of the included bed rest studies. Due to the broad data set that summarises the entire muscle evidence base, additional data on pre-bedrest fitness of participants was not extracted for analysis. While studies were selected that had healthy adults undergoing spaceflight simulation bedrest, individual physical condition was not considered beyond this. Therefore there may be some limitations to the transferability of astronauts who undergo training with space agencies prior to missions. However, a broad summary of the entire current evidence base with basic effect size analysis was the best way to try to address the overarching research questions, look for high level trends and present a summary of the current state of the complete evidence base.

4.5. Conclusions

The results of this review suggest that moderate effects on a range of muscle function parameters may occur within 7-14 days of unloading, with large effects within 35 days. Combined with identification of muscle performance requirements for future exploration mission tasks, these data, may support the design of CM programmes to optimise their efficient use without compromising crew safety and mission success. However, the data suggests CM are likely to still be needed for longer transit/orbital periods of 14-28+ days, such as a prolonged Lunar orbit, deep space exploration, or a Mars mission, as moderate effects occur between 7-14 days and large effects by 28 days for most muscle outcomes. However, if large effect sizes occur only after 28-35 days, to save resources, space agencies might consider short missions without exercise CM, or fixed periods of abstinence during longer μG exposures, if they could be confident that moderate changes in muscle performance could be reversed in-flight. Finally, several research gaps are highlighted for future bed rest studies in which standardised time points for measurements should be used and clear information provided on sunlight exposure control, fixed daily routine and control of any confounding factors.

Author contributions:

Winnard, A.: Initial concept ideas, protocol planning and drafting, search screening, analysing, drafting all manuscript versions, corresponding author
Scott, J.: Methods advice, protocol drafting, approving final draft
Waters, N.: Data extraction, analysis, drafting final version.
Vance, M.: Protocol planning, search screening, data analysis, drafting text and checking final version.
Caplan, N.: Protocol planning, search screening, methods advice, manuscript drafting and approving final version.

There are no conflicts of interest or funding sources to declare within the author team beyond author employment as already stated on title page.
Analysed study list:

1. (Akima, Kubo et al. 2000)
2. (Akima, Ushiyama et al. 2003)
3. (Akima, Katayama et al. 2005)
4. (Akima, Ushiyama et al. 2007)
5. (Alkner and Tesch 2004)
6. (Alkner, Norrbrand et al. 2016)
7. (Arbeille, Kerbeci et al. 2009)
8. (Bamman, Hunter et al. 1997)
9. (Belavy, Richardson et al. 2007)
10. (Belavy, Hides et al. 2008)
11. (Belavy, Miokovic et al. 2009)
12. (Belavy, Miokovic et al. 2009)
13. (Belavy, Armbrecht et al. 2010)
14. (Belavy, Armbrecht et al. 2011)
15. (Belavy, Ohshima et al. 2011)
16. (Belavy, Bansmann et al. 2011)
17. (Belavy, Miokovic et al. 2013)
18. (Belavy, Gast et al. 2017)
19. (Berg, Larsson et al. 1997)
20. (Berg, Eiken et al. 2007)
21. (Berry, Berry et al. 1993)
22. (Buehring, Belavy et al. 2011)
23. (Caiozzo, Haddad et al. 2009)
24. (Cescon and Gazzoni 2010)
25. (Convertino, Doerr et al. 1989)
26. (de Boer, Seynnes et al. 2008)
27. (Dudley, Duvoisin et al. 1989)
28. (Duvoisin, Convertino et al. 1989)
29. (Ellis, Kirby et al. 1993)
30. (English, Ploutz-Snyer et al. 2011)
31. (English, Mettler et al. 2016)
32. (Ferrando, Stuart et al. 1995)
33. (Ferretti, Berg et al. 2001)
34. (Fu, Wang et al. 2016)
35. (Funato, Matsuo et al. 1997)
36. (Gast, John et al. 2012)
37. (Germain, Guell et al. 1995)
38. (Greenleaf, Van Beaumont et al. 1983)
39. (Greenleaf, Bernauer et al. 1989)
40. (Greenleaf, Lee et al. 1994)
41. (Holguin, Muir et al. 2007)
42. (Holt, Macias et al. 2016)
43. (Kawashima, Akima et al. 2004)
44. (Koryak 1995)
45. (Koryak 1996)
46. (Koryak 1998)
47. (Koryak 1998)
48. (Koryak 1999)
49. (Koryak 2002)
50. (Koryak 2010)
51. (Koryak 2014)
52. (Kouzaki, Masani et al. 2007)
53. (Krainski, Hastings et al. 2014)
54. (LeBlanc, Gogia et al. 1988)
55. (Lee, Schneider et al. 2014)
56. (Macias, Cao et al. 2007)
57. (Miokovic, Armbrecht et al. 2011)
58. (Miokovic, Armbrecht et al. 2012)
59. (Miokovic, Armbrecht et al. 2014)
60. (Muir, Judex et al. 2011)
61. (Mulder, Stegeman et al. 2006)
62. (Mulder, Kuebler et al. 2007)
63. (Mulder, Gerrits et al. 2008)
64. (Mulder, Horstman et al. 2009)
65. (Mulder, Gerrits et al. 2009)
66. (Narici, Kayser et al. 1997)
67. (Pisot, Narici et al. 2008)
68. (Portero, Vanhoutte et al. 1996)
69. (Reeves, Maganaris et al. 2002)
70. (Rittweger, Frost et al. 2005)
71. (Rittweger, Moller et al. 2013)
72. (Schneider, Lee et al. 2016)
73. (Shinohara, Yoshitake et al. 2003)
74. (Trappe, Trappe et al. 2001)
75. (Trappe, Burd et al. 2007)

Not analysed study list:

1. (Belavy, Richardson et al. 2007)
2. (Belavy, Ng et al. 2010)
3. (Belavy, Wilson et al. 2012)
4. (Biolo, Agostini et al. 2008)
5. (Cavanagh, Rice et al. 2016)
6. (Shenkman, Kozlovskaya et al. 1997)
7. (Amorim, Schneider et al. 2006)
8. (Rittweger and Felsenberg 2009)
9. (Koriak Iu 2010)
10. (Koriak Iu 2012)
11. (Koriak Iu 2013)
12. (Koryak 1994)
13. (Bamman and Caruso 2000)
14. (Bamman 1996)
15. (Felsenberg, Belavy et al. 2009)
16. (Ferretti 1997)
17. (Greenleaf, Bernauer et al. 1994)
18. (Glogor'eva and Kozlovskaia 1987)
19. (Guo, Guo et al. 2001)
20. (Hargens, Watenpaugh et al. 2003)
21. (Judith C. Hayes, Roper et al. 1992)
22. (Ito, Torikoshi et al. 1994)
23. (Jaweed, Grana et al. 1995)
24. (Koryak 1995)
25. (Kozlovskaia, Grigor'eva et al. 1984)
26. (LeBlanc, Schneider et al. 1992)
27. (LeBlanc, Rowe et al. 1997)
28. (Liu, Huang et al. 2003)
29. (Macias, Schneider et al. 2008)
30. (Meuche, Schneider et al. 2006)
31. (Meuche, Schneider et al. 2005)
32. (Milesi, Capelli et al. 1997)
33. (Miyoshi, Sato et al. 2001)
34. (Moriggi, Vasso et al. 2010)
35. (Mulder, Horstman et al. 2011)
36. (Netreba, Khusnutdinova et al. 2004)
37. (Scott, Martin et al. 2017)
Simulated Weightbearing Exercise with Whole Body Vibration Reduces Lumbar Spine Deconditioning in Bed Exercise during bed
superficial lumbo


1023 Siconolfi (1992) "Eccentric and Concentric Muscle Performance Following 7 Days of Simulated Weightlessness." NASA
1024 1025 Technical Reports Server.
1029 1029 Koriak, Iu, A. (2010). "[Neuromuscular responses of the triceps surae muscle to prolonged passive stretch of the foot
1030 extensor muscles under conditions of simulated microgravity]." Fiziol Zh 56(5): 62-76.
1032 change as a result of a long-term bed-rest]." Fiziol Zh 58(2): 66-79.
1033 1033 Koriak, Iu, A. (2013). "[Influence of physical training under conditions of 120-day simulated microgravity on contractile
1034 properties and musculo-tendinous stiffness of the triceps surae muscle]." Fiziol Zh 59(2): 71-84.
1036 P76-79.
1037 Physiol 74(1-2): 133-140.
1037 1037 Koryak, Y. (1998). "Effect of 120 days of bed-rest with and without countermeasures on the mechanical properties of the
1052 head down bed rest on dynamic posture equilibrium and motor coordination]." Space Med Med Eng (Beijing) 16(4): 264-268.
Travel: 845-120


Figures

Captions:

1. **Fig. 1** PRISMA flow diagram of inclusion/exclusion process
2. **Fig. 2** Funnel plot of all effects
3. **Fig. 3** Effect size plots for muscle volume over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
4. **Fig. 4** Effect size plots for muscle cross sectional over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
5. **Fig. 5** Effect size plots for torques and strength area over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
6. **Fig. 6** Effect size plots for contractile work capacity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
7. **Fig. 7** Effect size plots for muscle thickness over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
8. **Fig. 8** Effect size plots for peak power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
9. **Fig. 9** Effect size plots for EMG muscle activity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
10. **Fig. 10** Effect size plots for MVC during one rep max over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
11. **Fig. 11** Effect size plots for power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
12. **Fig. 12** Effect size plots for performance based over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid
13. **Fig. 13** Mission profiles for 180 day surface stay Lunar mission (bottom) and 493 day surface stay Mars mission (top), adapted from HUMEX (Horneck, Fackius et al. 2003, Horneck, Fackius et al. 2006)
Figure 1 PRISMA flow diagram of inclusion/exclusion process
Figure 2 Funnel plot of all effects
Figure 3 Effect size plots for muscle volume over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 4 Effect size plots for muscle cross sectional area over time from individual
(grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 5 Effect size plots for torques and strength area over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 6 Effect size plots for contractile work capacity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 7 Effect size plots for muscle thickness over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 8 Effect size plots for peak power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 9 Effect size plots for EMG muscle activity over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 10 Effect size plots for MVC during one rep max over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 11 Effect size plots for power over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 12 Effect size plots for performance based over time from individual (grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect magnitudes and average effect trend line overlaid.
Figure 13 Mission profiles for 180 day surface stay Lunar mission (bottom) and 493 day surface stay Mars mission (top), adapted from HUMEX (Horneck, Facius et al. 2003, Horneck, Facius et al. 2006)
Tables

Main tables (to be included as indicated in the main manuscript):

1. Search strategy for database literature search.
2. Characteristics of analysed studies

Supplementary data tables (to be made available online only and not included in the main manuscript)

3. Average effect sizes over time for muscle volumes
4. Average effect sizes over time for muscle cross sectional areas
5. Average effect sizes over time for torques and strength
6. Average effect sizes over time for contractile work capacity
7. Average effect sizes over time for muscle thickness
8. Average effect sizes over time for peak power
9. Average effect sizes over time for EMG muscle activity
10. Average effect sizes over time for MVC during one rep max
11. Average effect sizes over time for power
12. Average effect sizes over time for EMG muscle activity
Table 1 Search strategy for database literature search.

<table>
<thead>
<tr>
<th>Search number</th>
<th>Term</th>
<th>Keywords in Boolean logic format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Microgravity</td>
<td>“astronaut” OR “spaceflight OR “space flight OR “space*” OR “weightless*” OR “microgravity” OR “micro gravity”</td>
</tr>
<tr>
<td>2</td>
<td>Bed rest</td>
<td>“bed-rest” OR “bedrest” OR “bed rest” OR “dry immersion”</td>
</tr>
<tr>
<td>3</td>
<td>Muscle</td>
<td>“musc*” OR “strength*”</td>
</tr>
<tr>
<td>4</td>
<td>Combined</td>
<td>1 AND 2 AND 3</td>
</tr>
</tbody>
</table>
Table 2 Characteristics of analysed studies

<table>
<thead>
<tr>
<th>Study (analysis cross reference no.)</th>
<th>Design</th>
<th>n</th>
<th>Outcomes</th>
<th>Bed rest quality tool</th>
<th>QUIPS risk of bias tool</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Days 1 2 3 4 5 6 7</td>
<td>OVERALL 1 2 3 4 5 6</td>
</tr>
<tr>
<td>Akima et al., 2000&lt;sup&gt;1&lt;/sup&gt;</td>
<td>RCT</td>
<td>4</td>
<td>Cross-sectional area, torque, volume.</td>
<td>20 y ? ? y y y y</td>
<td>M L n/a L H L H</td>
</tr>
<tr>
<td>Akima et al., 2003&lt;sup&gt;2&lt;/sup&gt;</td>
<td>RCT</td>
<td>6</td>
<td>Cross-sectional area, torque.</td>
<td>20 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Akima et al., 2005&lt;sup&gt;3&lt;/sup&gt;</td>
<td>RCT</td>
<td>5</td>
<td>Activity (EMG), volume, MVC.</td>
<td>20 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Akima et al., 2007&lt;sup&gt;4&lt;/sup&gt;</td>
<td>RCT</td>
<td>6</td>
<td>Muscle Volume.</td>
<td>20 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Alkner and Tesch 2004&lt;sup&gt;5&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Volume, MVC, force, power, torque, activity (EMG).</td>
<td>90 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Alkner et al., 2016&lt;sup&gt;6&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Activity (EMG), force,</td>
<td>90 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Arbeille et al., 2009&lt;sup&gt;7&lt;/sup&gt;</td>
<td>RCT</td>
<td>8</td>
<td>Volume</td>
<td>60 y y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Bamman et al., 1997&lt;sup&gt;8&lt;/sup&gt;</td>
<td>RCT</td>
<td>8</td>
<td>MVC, activity (EMG), torque, Power, work.</td>
<td>14 y y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2007(a)&lt;sup&gt;9&lt;/sup&gt;</td>
<td>RCT</td>
<td>10</td>
<td>Cross-sectional area.</td>
<td>56 n y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2008&lt;sup&gt;10&lt;/sup&gt;</td>
<td>RCT</td>
<td>10</td>
<td>Cross-sectional area.</td>
<td>56 ? y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2009(a)&lt;sup&gt;11&lt;/sup&gt;</td>
<td>RCT</td>
<td>10</td>
<td>Volume.</td>
<td>56 ? y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2009(b)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>RCT</td>
<td>10</td>
<td>Volume.</td>
<td>56 ? y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2010(b)&lt;sup&gt;13&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Cross-sectional area</td>
<td>60 y y y y y y y</td>
<td>H L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2011(a)&lt;sup&gt;14&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Cross-sectional area</td>
<td>60 y y y y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2011(b)&lt;sup&gt;15&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Volume</td>
<td>90 y y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2011(c)&lt;sup&gt;16&lt;/sup&gt;</td>
<td>CO</td>
<td>7</td>
<td>Cross-sectional area, Muscle Signal Intensity</td>
<td>21 ? y ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2013&lt;sup&gt;17&lt;/sup&gt;</td>
<td>RCT</td>
<td>9</td>
<td>Volume</td>
<td>60 y y y y y y y</td>
<td>H L n/a L M L H</td>
</tr>
<tr>
<td>Belavy et al., 2016&lt;sup&gt;18&lt;/sup&gt;</td>
<td>RCT</td>
<td>8</td>
<td>Muscle Atrophy</td>
<td>56 ? y ? y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Berg et al., 1997&lt;sup&gt;19&lt;/sup&gt;</td>
<td>RCT</td>
<td>7</td>
<td>Torque, activity (EMG), angular velocity, fibre types/size, cross-sectional area</td>
<td>42 y ? ? y y y y</td>
<td>M L n/a L M L H</td>
</tr>
<tr>
<td>Berg et al., 2007&lt;sup&gt;20&lt;/sup&gt;</td>
<td>RCT</td>
<td>5</td>
<td>MVC, Cross-sectional area</td>
<td>35 n y ? y y y y</td>
<td>H L n/a L H L H</td>
</tr>
<tr>
<td>Berry et al., 1993&lt;sup&gt;21&lt;/sup&gt;</td>
<td>CO</td>
<td>6</td>
<td>Cross-sectional area</td>
<td>30 y y y y y y y</td>
<td>H L n/a L M L H</td>
</tr>
<tr>
<td>Buehling et al., 2011&lt;sup&gt;22&lt;/sup&gt;</td>
<td>RCT</td>
<td>10</td>
<td>MVC, activity, Jump Power, Jump Height</td>
<td>56 n y y y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Caiozzo et al., 2009&lt;sup&gt;23&lt;/sup&gt;</td>
<td>RCT</td>
<td>7</td>
<td>Torque, cross-sectional area</td>
<td>21 y y y y y y y</td>
<td>H L n/a L M L H</td>
</tr>
<tr>
<td>Cescon &amp; Gazzoni 2010&lt;sup&gt;24&lt;/sup&gt;</td>
<td>RCT</td>
<td>4</td>
<td>Single and Global motor unit conduction velocity</td>
<td>14 y y y y y y y</td>
<td>L L n/a L M L H</td>
</tr>
<tr>
<td>Convertino et al., 1989&lt;sup&gt;25&lt;/sup&gt;</td>
<td>B&amp;A</td>
<td>8</td>
<td>cross-sectional area</td>
<td>30 y ? ? y y y y</td>
<td>H L n/a L M L H</td>
</tr>
<tr>
<td>De Boer et al., 2008&lt;sup&gt;26&lt;/sup&gt;</td>
<td>B&amp;A</td>
<td>10</td>
<td>Thickness</td>
<td>35 n y y y y y y</td>
<td>M L n/a L H L H</td>
</tr>
<tr>
<td>Study/analysis cross reference no.</td>
<td>Design</td>
<td>n</td>
<td>Outcomes</td>
<td>Dur</td>
<td>Red rest quality tool</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------</td>
<td>---</td>
<td>--------------------------------------------------------------------------</td>
<td>-----</td>
<td>----------------------</td>
</tr>
<tr>
<td>Ellis et al., 1993</td>
<td>CS</td>
<td>5</td>
<td>Thickness</td>
<td>30</td>
<td>y y y y y ? y 6</td>
</tr>
<tr>
<td>English et al., 2011</td>
<td>B&amp;A</td>
<td>8</td>
<td>Torque</td>
<td>60</td>
<td>n y y y y ? y 5</td>
</tr>
<tr>
<td>English et al., 2016</td>
<td>RCT</td>
<td>9</td>
<td>Torque and work</td>
<td>14</td>
<td>? y ? y y ? y 4</td>
</tr>
<tr>
<td>Ferrando et al., 1995</td>
<td>B&amp;A</td>
<td>6</td>
<td>Volume</td>
<td>7</td>
<td>? y ? y y ? y 4</td>
</tr>
<tr>
<td>Ferretti et al., 2001</td>
<td>TS</td>
<td>7</td>
<td>Cross-sectional area, jump power</td>
<td>42</td>
<td>y ? ? y y ? y 4</td>
</tr>
<tr>
<td>Fu et al., 2016</td>
<td>TS</td>
<td>8</td>
<td>Activity (EMG), force</td>
<td>45</td>
<td>y y ? y y y ? y 5</td>
</tr>
<tr>
<td>Gast et al., 2012</td>
<td>RCT</td>
<td>9</td>
<td>Jump height &amp; power, sit-to-stand tests, sprint time, leg press (1RM)</td>
<td>60</td>
<td>y y y y y y y ? y 6</td>
</tr>
<tr>
<td>Germain et al., 1995</td>
<td>RCT</td>
<td>6</td>
<td>Torque</td>
<td>28</td>
<td>y ? ? y y ? y 4</td>
</tr>
<tr>
<td>Greenleaf et al., 1989</td>
<td>RCT</td>
<td>5</td>
<td>Work, torque</td>
<td>30</td>
<td>y y ? y y y ? y 5</td>
</tr>
<tr>
<td>Greenleaf et al., 1994(a)</td>
<td>RCT</td>
<td>5</td>
<td>Volume</td>
<td>30</td>
<td>y y ? y y y ? ? 4</td>
</tr>
<tr>
<td>Holguin et al., 2007</td>
<td>RCT</td>
<td>11</td>
<td>Volume</td>
<td>90</td>
<td>Y Y ? Y Y ? Y Y 5</td>
</tr>
<tr>
<td>Holt et al., 2016</td>
<td>RCT</td>
<td>8</td>
<td>Cross-sectional area</td>
<td>60</td>
<td>y y y y y y y ? y 6</td>
</tr>
<tr>
<td>Kawasaki et al., 2004</td>
<td>B&amp;A</td>
<td>10</td>
<td>Cross-sectional area</td>
<td>20</td>
<td>n y y y y y y y 4</td>
</tr>
<tr>
<td>Koryak 1995(a)</td>
<td>B&amp;A</td>
<td>6</td>
<td>MVC, force, time to peak tension, total contraction time</td>
<td>120</td>
<td>y ? ? y y y y 4</td>
</tr>
<tr>
<td>Koryak 1996</td>
<td>B&amp;A</td>
<td>6</td>
<td>MVC, twitch tension, time to peak tension, total contraction time, surface action potentials</td>
<td>7</td>
<td>n ? ? y ? ? y 2</td>
</tr>
<tr>
<td>Koryak 1998(b)</td>
<td>RCT</td>
<td>4</td>
<td>MVC, evoked tetanic tension, maximal twitch tension, twitch time-to-peak tension, total contraction time</td>
<td>120</td>
<td>y ? ? y y ? y 4</td>
</tr>
<tr>
<td>Koryak 1999</td>
<td>B&amp;A</td>
<td>10</td>
<td>MVC, tension of maximal twitch, evoked tetanic tension, time to peak tension, total contraction time</td>
<td>120</td>
<td>y ? ? y y y y 4</td>
</tr>
<tr>
<td>Koryak 2002</td>
<td>B&amp;A</td>
<td>6</td>
<td>Tension of maximal twitch, evoked tetanic tension, time to peak tension, total contraction time, surface action potential</td>
<td>7</td>
<td>n ? ? y y ? y 3</td>
</tr>
<tr>
<td>Study (analysis cross reference no.)</td>
<td>Design</td>
<td>n</td>
<td>Outcomes</td>
<td>Days</td>
<td>Bed rest quality tool</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------</td>
<td>---</td>
<td>----------</td>
<td>------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 2 3 4 5 6 7</td>
</tr>
<tr>
<td>Koryak 2010[50]</td>
<td>RCT</td>
<td>6</td>
<td>MVC, twitch tension, time to peak tension, total contraction time.</td>
<td>60</td>
<td>y y y y y y y 5</td>
</tr>
<tr>
<td>Koryak 2014[51]</td>
<td>RCT</td>
<td>6</td>
<td>Volume, electromyogram.</td>
<td>20</td>
<td>y y y y y y y 4</td>
</tr>
<tr>
<td>Kouzaki et al., 2007[52]</td>
<td>RCT</td>
<td>6</td>
<td>Volume, electromyogram.</td>
<td>20</td>
<td>y y y y y y y 4</td>
</tr>
<tr>
<td>Krainiski et al., 2014[53]</td>
<td>RCT</td>
<td>9</td>
<td>Volume.</td>
<td>35</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>LeBlanc et al., 1988[54]</td>
<td>B&amp;A</td>
<td>9</td>
<td>Cross-sectional area.</td>
<td>35</td>
<td>n y y y y y 4</td>
</tr>
<tr>
<td>Lee et al., 2014[55]</td>
<td>RCT</td>
<td>24</td>
<td>Torque, IRM, lean mass.</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>Macias et al., 2007[56]</td>
<td>RCT</td>
<td>15</td>
<td>Strength, torque.</td>
<td>28</td>
<td>y y y y y y 4</td>
</tr>
<tr>
<td>Miokovic et al., 2011[57]</td>
<td>RCT</td>
<td>9</td>
<td>Volume.</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>Miokovic et al., 2012[58]</td>
<td>RCT</td>
<td>9</td>
<td>Volume.</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>Miokovic et al., 2014[59]</td>
<td>RCT</td>
<td>8</td>
<td>Volume.</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>Muir et al., 2011[60]</td>
<td>RCT</td>
<td>13</td>
<td>Strength, postural stability.</td>
<td>90</td>
<td>y y y y y y 5</td>
</tr>
<tr>
<td>Mulder et al., 2006[61]</td>
<td>RCT</td>
<td>10</td>
<td>Cross-sectional area.</td>
<td>56</td>
<td>n y y y y y 3</td>
</tr>
<tr>
<td>Mulder et al., 2007[62]</td>
<td>RCT</td>
<td>10</td>
<td>Torque.</td>
<td>56</td>
<td>y y y y y y y 4</td>
</tr>
<tr>
<td>Mulder et al., 2008[63]</td>
<td>RCT</td>
<td>8</td>
<td>Time to peak tension.</td>
<td>56</td>
<td>y y y y y y 4</td>
</tr>
<tr>
<td>Mulder et al., 2009(a)[64]</td>
<td>RCT</td>
<td>9</td>
<td>Cross-sectional area, activity (EMG).</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
<tr>
<td>Mulder et al., 2009(b)[65]</td>
<td>RCT</td>
<td>10</td>
<td>Knee Extensor MVC.</td>
<td>56</td>
<td>N y y y y y y 4</td>
</tr>
<tr>
<td>Narici et al., 1997[66]</td>
<td>CS</td>
<td>8</td>
<td>Cross-sectional area, force.</td>
<td>17</td>
<td>y y y y y y 2</td>
</tr>
<tr>
<td>Pisot et al., 2008[67]</td>
<td>B&amp;A</td>
<td>10</td>
<td>Contraction time, muscle maximal displacement</td>
<td>35</td>
<td>n y y y y y y 4</td>
</tr>
<tr>
<td>Portero et al., 1996[68]</td>
<td>B&amp;A</td>
<td>12</td>
<td>MVC.</td>
<td>30</td>
<td>y y y y y y 3</td>
</tr>
<tr>
<td>Reeves et al., 2002[69]</td>
<td>RCT</td>
<td>6</td>
<td>Force, resting fascicle length, fascicle length at mvc</td>
<td>90</td>
<td>y y y y y y y 5</td>
</tr>
<tr>
<td>Rittweger et al., 2005[70]</td>
<td>RCT</td>
<td>9</td>
<td>Cross-sectional area.</td>
<td>90</td>
<td>y y y y y y y 4</td>
</tr>
<tr>
<td>Rittweger et al., 2013[71]</td>
<td>RCT</td>
<td>9</td>
<td>Cross-sectional area.</td>
<td>90</td>
<td>y y y y y y y 4</td>
</tr>
<tr>
<td>Schneider et al., 2016[72]</td>
<td>RCT</td>
<td>8</td>
<td>Torque, work, lean mass.</td>
<td>30</td>
<td>y y y y y y y 5</td>
</tr>
<tr>
<td>Shinoara et al., 2003[73]</td>
<td>RCT</td>
<td>6</td>
<td>MVC, activity EMG</td>
<td>20</td>
<td>y y y y y y 5</td>
</tr>
<tr>
<td>Trappe et al., 2001[74]</td>
<td>CS</td>
<td>8</td>
<td>Torque.</td>
<td>17</td>
<td>y y y y y y y 3</td>
</tr>
<tr>
<td>Trappe et al., 2007[75]</td>
<td>RCT</td>
<td>8</td>
<td>Volume Force</td>
<td>60</td>
<td>y y y y y y y 6</td>
</tr>
</tbody>
</table>

Bed rest quality scores: 1 6 degrees head down tilt, 2 controlled diet, 3 fixed daily routine, 4 standardised bed rest phases, 5 uninterrupted bed rest, 6 restricted sunlight exposure, 7 same outcome measures for all. Quips risk of bias tool: 1 participation, 2, attrition, 3 prognostic factor measurement, 4 confounding factors, 5 statistical analysis and reporting, 6 overall quality score.

Supplementary data tables (to be made available online only and not included in the published paper)

3. Average effect sizes over time for muscle volumes
4. Average effect sizes over time for muscle cross sectional areas
5. Average effect sizes over time for torques and strength
6. Average effect sizes over time for contractile work capacity
7. Average effect sizes over time for muscle thickness
8. Average effect sizes over time for peak power
9. Average effect sizes over time for muscle activity
10. Average effect sizes over time for MVC during one rep max
11. Average effect sizes over time for power
12. Average effect sizes over time for performance based
Table 3 Average effect sizes over time for muscle volumes

<table>
<thead>
<tr>
<th></th>
<th>Days</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7</td>
<td>14</td>
<td>20</td>
<td>27</td>
<td>28</td>
<td>29</td>
<td>35</td>
<td>42</td>
<td>55</td>
<td>56</td>
</tr>
<tr>
<td>Plantar Dorsiflexor Muscles</td>
<td>-0.3</td>
<td>-1.0</td>
<td>-0.4</td>
<td>-0.9</td>
<td>-1.8</td>
<td>-1.2</td>
<td>-1.7</td>
<td>-2.2</td>
<td>-1.3</td>
<td>-3.2</td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td>1.1</td>
<td>1.0^11,12</td>
<td>1.3^15,56</td>
<td>1.0^58,90</td>
<td>1.1^11,12</td>
<td>1.0^58,90</td>
<td>1.1^15</td>
<td>1.2^11,12</td>
<td>1.0^58,90</td>
<td>1.411,12</td>
</tr>
<tr>
<td>Dorsiflexor Muscles</td>
<td>-0.4</td>
<td>-0.1</td>
<td>-0.4</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.8</td>
<td>-0.7</td>
<td>-2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsiflexor Muscles</td>
<td>0.9^11,12</td>
<td>1.2^14,52</td>
<td>1.0^58,90</td>
<td>0.9^11,12</td>
<td>0.9^11,12</td>
<td>1.0^58,90</td>
<td>1.3^11,12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>-1.3</td>
<td>-0.5</td>
<td>-0.7</td>
<td>-1.7</td>
<td>-0.8</td>
<td>-0.6</td>
<td>-2.2</td>
<td>-1.1</td>
<td>-2.8</td>
<td>-1.3</td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>1.12^11,12</td>
<td>1.3^13,34</td>
<td>1.0^58,90</td>
<td>1.2^11,12</td>
<td>1.0^58,90</td>
<td>1.3^11,12</td>
<td>1.1^58,90</td>
<td>1.411,12</td>
<td>1.3^11,12</td>
<td></td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td>-1.1</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-1.0</td>
<td>-1.8</td>
<td>-1.1</td>
<td>-2.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td>1.1^11,12</td>
<td>1.3^13,34</td>
<td>1.0^58,90</td>
<td>1.411,12</td>
<td>1.0^58,90</td>
<td>1.3^11,12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Adductor Muscles</td>
<td>-0.6</td>
<td>1.2</td>
<td>-0.2</td>
<td>-0.7</td>
<td>-1.1</td>
<td>-0.4</td>
<td>-1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Adductor Muscles</td>
<td>1.1^11,12</td>
<td>1.5^14</td>
<td>1.0^58,90</td>
<td>1.411,12</td>
<td>1.1^11,12</td>
<td>1.0^58,90</td>
<td>1.1^11,12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gluteal Muscles</td>
<td>-0.6</td>
<td></td>
<td>-0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gluteal Muscles</td>
<td>1^17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td>-0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td>0.9^17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Lower Limb Muscles</td>
<td>-0.2</td>
<td>-0.7</td>
<td>-0.5</td>
<td>-0.8</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-0.3</td>
<td>-0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Lower Limb Muscles</td>
<td>1.2^17</td>
<td>1^12</td>
<td>1.3^13,34</td>
<td>1.1^58,90,97</td>
<td>1^15</td>
<td>1^12</td>
<td>0.9^58,90,97</td>
<td>1.1^12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erector Spinae Muscles</td>
<td>0.3</td>
<td></td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erector Spinae Muscles</td>
<td>0.9^17</td>
<td></td>
<td>0.9^17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multifidus Muscle</td>
<td>-0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multifidus Muscle</td>
<td>1^15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Trunk Muscles</td>
<td>0.4</td>
<td></td>
<td>0.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Trunk Muscles</td>
<td>0.9^17</td>
<td></td>
<td>0.9^17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
Table 4 Average effect sizes over time for muscle cross sectional areas

<table>
<thead>
<tr>
<th>Days</th>
<th>2</th>
<th>7</th>
<th>9</th>
<th>10</th>
<th>14</th>
<th>16</th>
<th>20</th>
<th>21</th>
<th>27</th>
<th>28</th>
<th>29</th>
<th>30</th>
<th>35</th>
<th>37</th>
<th>42</th>
<th>47</th>
<th>55</th>
<th>56</th>
<th>60</th>
<th>89</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.2^{20}</td>
<td>1.2^{20}</td>
<td>1.2^{20}</td>
<td>1.2^{20}</td>
<td>1.2^{12}</td>
<td>1.1^{15}</td>
<td>1.2^{20,71}</td>
<td>1.2^{20}</td>
<td>1.0^{21,25}</td>
<td>1.1^{20,54}</td>
<td>1.2^{24}</td>
<td>1.8^{20,51}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.3</td>
<td>-0.8</td>
<td>-2.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>-0.9</td>
<td>-0.6</td>
<td>-1.8</td>
<td>-4.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsiflexor Muscles</td>
<td>-0.2</td>
<td>-1.3</td>
<td>-0.3</td>
<td>-0.2</td>
<td>-1.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.7</td>
<td>-0.1</td>
<td>-0.4</td>
<td>-0.5</td>
<td>-1.3</td>
<td>-0.7</td>
<td>-1.1</td>
<td>-1.5</td>
<td>-1.5</td>
<td>-1.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td>-0.4</td>
<td>-0.2</td>
<td>-0.2</td>
<td>0.9^{11}</td>
<td>0.9^{11}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Adductor Muscles</td>
<td>0.2</td>
<td>0.0</td>
<td>0.2</td>
<td>1.1^{16}</td>
<td>0.9^{13,14}</td>
<td>0.0</td>
<td>0.9^{13,14}</td>
<td>0.0</td>
<td>1.0^{22}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gluteal Muscles</td>
<td>0.2</td>
<td>0.0</td>
<td>0.2</td>
<td>1.2^{20,21}</td>
<td>1.1^{13}</td>
<td>-0.1</td>
<td>-0.1</td>
<td>-0.1</td>
<td>1.0^{20,21}</td>
<td>1.1^{13}</td>
<td>-1.1</td>
<td>-1.1</td>
<td>-1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td>-0.6</td>
<td>-1.2</td>
<td>-1.0</td>
<td>1.4^{1}</td>
<td>1.4^{1}</td>
<td>1.4^{1}</td>
<td>1.4^{1}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Lower Limb Muscles</td>
<td>-0.8</td>
<td>-0.5</td>
<td>-0.6</td>
<td>0.6</td>
<td>0.8</td>
<td>1.1^{16}</td>
<td>1.0^{13,14}</td>
<td>1.0^{13,14}</td>
<td>1.0^{13,14}</td>
<td>1.0^{13,14}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erector Spinae Muscles</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.6</td>
<td>1.0^{14}</td>
<td>1.0^{14}</td>
<td>1.0^{14}</td>
<td>1.0^{14}</td>
<td>1.0^{14}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multifidus Muscle</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td></td>
</tr>
<tr>
<td>Other Trunk Muscle</td>
<td>-0.4</td>
<td>-0.3</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td>-0.4</td>
<td></td>
</tr>
<tr>
<td>Upper Limb Muscles</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.9</td>
<td></td>
</tr>
<tr>
<td>Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 5: Average effect sizes over time for torques and strength

<table>
<thead>
<tr>
<th>Days</th>
<th>4</th>
<th>7</th>
<th>10</th>
<th>14</th>
<th>17</th>
<th>20</th>
<th>21</th>
<th>24</th>
<th>26</th>
<th>28</th>
<th>30</th>
<th>38</th>
<th>42</th>
<th>55</th>
<th>56</th>
<th>60</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td>-0.3</td>
<td>0.1</td>
<td>-0.4</td>
<td>-0.2</td>
<td>-0.4</td>
<td>-0.7</td>
<td>-1.7</td>
<td>-1.7</td>
<td>-2.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.0^{11.8}</td>
<td>1.0^{14}</td>
<td>1.1^{2}</td>
<td>1.1^{23}</td>
<td>1.0^{72}</td>
<td>0.8^{58}</td>
<td>1.1^{64}</td>
<td>0.7^{55}</td>
<td>1.1^{560}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsi Flexor Muscles</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-0.9</td>
<td>-0.3</td>
<td>0.6</td>
<td>0.8^{50}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.0^{72}</td>
<td>0.8^{58}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>-0.2</td>
<td>-0.3</td>
<td>-0.3</td>
<td>-0.8</td>
<td>-0.4</td>
<td>-0.7</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-0.5</td>
<td>-0.6</td>
<td>-0.9</td>
<td>-2.2</td>
<td>-2.0</td>
<td>-1.0</td>
<td>-1.7</td>
<td>-3.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.9^{65}</td>
<td>0.9^{65}</td>
<td>0.9^{65}</td>
<td>1.0^{11}</td>
<td>0.9^{65}</td>
<td>1.4^{1}</td>
<td>0.7^{23}</td>
<td>0.9^{65}</td>
<td>1.1^{77.72}</td>
<td>1.1^{77}</td>
<td>0.9^{65}</td>
<td>1.3^{19}</td>
<td>1.1^{64}</td>
<td>0.9^{62.65}</td>
<td>1.1^{62.91}</td>
<td>1.4^{620.6}</td>
<td></td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>-0.1</td>
<td>-0.4</td>
<td>-0.2</td>
<td>-0.7</td>
<td>-0.8</td>
<td>-1.7</td>
<td>-0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.9^{61}</td>
<td>0.9^{61}</td>
<td>0.9^{61}</td>
<td>0.9^{61}</td>
<td>1.0^{72}</td>
<td>1.1^{77}</td>
<td>1.0^{61}</td>
<td>1.0^{61}</td>
<td>0.7^{55}</td>
<td>0.8^{60}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Extensor Muscles</td>
<td>-0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.9^{53}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td>-0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.9^{53}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Trunk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Limb Muscles</td>
<td>-0.1</td>
<td>0.1</td>
<td>-0.4</td>
<td>-0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.2^{39}</td>
<td>1.2^{39}</td>
<td>0.7^{56}</td>
<td>0.9^{53}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table*
Table 6 Average effect sizes over time for contractile work capacity

<table>
<thead>
<tr>
<th>Days</th>
<th>Plantar Flexors</th>
<th>Quadriiceps</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td></td>
<td>1.0^3</td>
<td>0.9^31</td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
<table>
<thead>
<tr>
<th></th>
<th>Days</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>14</td>
<td>26</td>
<td>35</td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0&lt;sup&gt;26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsi Flexor Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.9&lt;sup&gt;26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0&lt;sup&gt;26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erector Spinae Muscles</td>
<td></td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
</tr>
<tr>
<td>Internal Oblique Muscle</td>
<td></td>
<td>-0.9</td>
<td>-0.9</td>
<td>-0.8</td>
<td>-0.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.0&lt;sup&gt;18&lt;/sup&gt;</td>
</tr>
<tr>
<td>Transversus Abdominis Muscle</td>
<td></td>
<td>-1.6</td>
<td>-1.4</td>
<td>-1.4</td>
<td>-1.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.1&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.1&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.1&lt;sup&gt;18&lt;/sup&gt;</td>
<td>1.1&lt;sup&gt;18&lt;/sup&gt;</td>
</tr>
<tr>
<td>Upper Limb Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.9&lt;sup&gt;26&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
### Table 8 Average effect sizes over time for peak power

<table>
<thead>
<tr>
<th></th>
<th>Days</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>56</td>
<td>60</td>
<td>62</td>
<td>90</td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.6</td>
<td>-2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.1^75</td>
<td>1.2^5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.4</td>
<td>-1.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.1^75</td>
<td>1.1^5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jump</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.6</td>
<td>-2.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.0^22</td>
<td>1.2^6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table.
<table>
<thead>
<tr>
<th>Muscle Type</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14</td>
</tr>
<tr>
<td>Plantar Flexor Muscles</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>1.0$^{3}$</td>
</tr>
<tr>
<td>Dorsi Flexor Muscles</td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td>1.4$^{22}$</td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>-0.5</td>
</tr>
<tr>
<td></td>
<td>-0.6</td>
</tr>
<tr>
<td></td>
<td>1.0$^{4}$</td>
</tr>
<tr>
<td>Erector Spinae Muscles</td>
<td>-0.3</td>
</tr>
<tr>
<td></td>
<td>-0.2</td>
</tr>
<tr>
<td>Mutifidus Muscle</td>
<td>-0.2</td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td>-0.2</td>
</tr>
<tr>
<td>Shoulder Muscles</td>
<td>-0.7</td>
</tr>
<tr>
<td></td>
<td>1.0$^{14}$</td>
</tr>
<tr>
<td>Forearm Muscles</td>
<td>-0.7</td>
</tr>
<tr>
<td></td>
<td>1.0$^{14}$</td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table.
Table 10 Average effect sizes over time for MVC during one rep max

<table>
<thead>
<tr>
<th>Days</th>
<th>6</th>
<th>7</th>
<th>10</th>
<th>13</th>
<th>15</th>
<th>17</th>
<th>20</th>
<th>26</th>
<th>28</th>
<th>30</th>
<th>35</th>
<th>45</th>
<th>56</th>
<th>60</th>
<th>62</th>
<th>90</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plantar Flexor Muscles</td>
<td>-0.7</td>
<td>-1.1</td>
<td>-0.3</td>
<td>-0.4</td>
<td>-0.8</td>
<td>-1.4</td>
<td>-2.1</td>
<td>-1.7</td>
<td>-2.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.2^{5,49}</td>
<td>1.1^{9}</td>
<td>1.0^{60}</td>
<td>1.1^{33}</td>
<td>0.9^{22}</td>
<td>1.3^{50}</td>
<td>1.3^{38}</td>
<td>1.1^{20,25}</td>
<td>1.5^{44,46,47,48,51}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorsi Flexor Muscles</td>
<td>-0.1</td>
<td>-0.1</td>
<td>1.0</td>
<td>0.5</td>
<td>-0.5</td>
<td>0.6^{33}</td>
<td>1.1^{9,38}</td>
<td>1.2^{4}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td>-0.5</td>
<td>-0.7</td>
<td>-0.8</td>
<td>-0.3</td>
<td>-1.4</td>
<td>-1.1</td>
<td>-1.5</td>
<td>-2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.3^{5}</td>
<td>1.3^{9}</td>
<td>1.3^{20,33}</td>
<td>1.0^{7,2}</td>
<td>1.4^{21}</td>
<td>0.6^{33}</td>
<td>1.1^{9,38}</td>
<td>1.2^{4}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td>-0.4</td>
<td>-0.8</td>
<td>-1.1</td>
<td>-0.6</td>
<td>-0.4</td>
<td>-0.6</td>
<td>-0.9</td>
<td>-1.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.3^{5}</td>
<td>1.3^{9}</td>
<td>1.3^{20,33}</td>
<td>1.0^{7,2}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip Flexor Muscle</td>
<td>-0.9</td>
<td>-1.0</td>
<td>1.0</td>
<td>0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other lower limb</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-0.6</td>
<td>-0.5</td>
<td>-0.9</td>
<td>1.3^{9}</td>
<td>1.3^{9}</td>
<td>1.3^{20,33}</td>
<td>1.0^{9}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other upper limb</td>
<td>0.0</td>
<td>0.2</td>
<td>-0.1</td>
<td>-0.2</td>
<td>-0.5</td>
<td>-0.1</td>
<td>-0.0</td>
<td>-0.0</td>
<td>-0.0</td>
<td>-0.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table.
<table>
<thead>
<tr>
<th>Muscle Type</th>
<th>Days</th>
<th>7</th>
<th>14</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plantar Flexor Muscles</td>
<td></td>
<td>-0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0[5]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadriceps Muscles</td>
<td></td>
<td>-0.6</td>
<td>-0.9</td>
<td>-1.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.3[35]</td>
<td>1.3[35]</td>
<td>1.5[35]</td>
</tr>
<tr>
<td>Hamstring Muscles</td>
<td></td>
<td>-0.1</td>
<td>-0.4</td>
<td>-0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.2[35]</td>
<td>1.2[35]</td>
<td>1.3[35]</td>
</tr>
<tr>
<td>Hip Flexor Muscles</td>
<td></td>
<td>-0.3</td>
<td>-0.5</td>
<td>-0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.2[35]</td>
<td>1.3[35]</td>
<td>1.3[35]</td>
</tr>
<tr>
<td>Other upper limb</td>
<td></td>
<td>-0.0</td>
<td>-0.2</td>
<td>-0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.2[35]</td>
<td>1.2[35]</td>
<td>1.3[35]</td>
</tr>
</tbody>
</table>

Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table.
**Table 12 Average effect sizes over time for performance based**

<table>
<thead>
<tr>
<th></th>
<th>Days</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14</td>
<td>30</td>
<td>42</td>
<td>44</td>
<td>56</td>
<td>60</td>
<td>62</td>
</tr>
<tr>
<td><strong>Endurance</strong></td>
<td>-1.1</td>
<td>-1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.1(^{33})</td>
<td>0.9(^{36})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Jumping</strong></td>
<td>-0.6</td>
<td>-2.0</td>
<td>-1.2</td>
<td>-2.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.1(^{19})</td>
<td>1.3(^{31})</td>
<td>1.0(^{22})</td>
<td>1.3(^{36})</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sit to stand</strong></td>
<td></td>
<td>-1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.0(^{39})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Balance</strong></td>
<td></td>
<td></td>
<td>1.2</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.8(^{50})</td>
<td>0.8(^{50})</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sprint time</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.1(^{39})</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table*